Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection
Attallah, A., El-Far, M., Abdel Fatah, M., Omran, M., Abdelrazek, M., Abdelhameed, G., Attallah, K., Ahmed, N., El-Sayes, E., Khedr, F., El-Dosoky, I. (2019). Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection. EKB Journal Management System, 5(2), 212-221. doi: 10.21608/jbaar.2019.141374
Abdelfattah M. Attallah; Mohamed El-Far; Mohy E. Abdel Fatah; Mohamed M. Omran; Mohamed A. Abdelrazek; Gamal. E Abdelhameed; Kareem A. Attallah; Nada A. Ahmed; Esraa A. El-Sayes; Fatma M. Khedr; Ibrahim El-Dosoky. "Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection". EKB Journal Management System, 5, 2, 2019, 212-221. doi: 10.21608/jbaar.2019.141374
Attallah, A., El-Far, M., Abdel Fatah, M., Omran, M., Abdelrazek, M., Abdelhameed, G., Attallah, K., Ahmed, N., El-Sayes, E., Khedr, F., El-Dosoky, I. (2019). 'Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection', EKB Journal Management System, 5(2), pp. 212-221. doi: 10.21608/jbaar.2019.141374
Attallah, A., El-Far, M., Abdel Fatah, M., Omran, M., Abdelrazek, M., Abdelhameed, G., Attallah, K., Ahmed, N., El-Sayes, E., Khedr, F., El-Dosoky, I. Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection. EKB Journal Management System, 2019; 5(2): 212-221. doi: 10.21608/jbaar.2019.141374

Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection

Journal of Bioscience and Applied Research
Article 7, Volume 5, Issue 2, June 2019, Page 212-221  XML PDF (579.8 K)
Document Type: Original Article
DOI: 10.21608/jbaar.2019.141374
View on SCiNiTO View on SCiNiTO
Authors
Abdelfattah M. Attallah email 1; Mohamed El-Far2; Mohy E. Abdel Fatah3; Mohamed M. Omran4; Mohamed A. Abdelrazek1; Gamal. E Abdelhameed1; Kareem A. Attallah1; Nada A. Ahmed1; Esraa A. El-Sayes1; Fatma M. Khedr1; Ibrahim El-Dosoky5
1Research & Development Department, Biotechnology Research Center, New Damietta, Egypt
2Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
3Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
4Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt
5Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract
Aim: Improvement of breast cancer (BrCa) control will be markedly supported by early detection. Owing to limitations of current diagnostic tools like mammography and ultrasound and lack of existing confirmed BrCa biomarkers, this study concerned the evaluation of some potential biomarkers and their combination in BrCa detection. Methods: Three hundred participant women; 200 with BrCa patients, 50 with benign breast diseases, and 50 healthy individuals were enrolled in this study. Serum levels of nuclear matrix protein-52 (NMP-52), collagen III, and matrix metalloproteinase-1 (MMP-1) were determined by ELISA. Results: Mean levels of NMP-52 (9.83±1.1 μg/ml), collagen III (22.6±3.2 μg/mL) and MMP-1 (3.6±0.3 μg/mL) in BrCa patients were significantly higher (P<0.0001) than benign (5.8±0.7, 12.2±1.3 and 2.6±0.23 μg/mL, respectively) and healthy (1.2±0.1, 6.0±0.2 and 1.66±0.04 μg/mL, respectively) groups. Also, these levels were associated with the tumor progression and may reflect the BrCa disease severity, high serum levels of these markers have been associated with tumor advanced stages (T3-T4), high grade (G3), and large size (>2cm). Diagnostic scores combined these markers revealed valuable power (AUC=0.83, 78% sensitivity, 75% specificity) in BrCa diagnosis. This power is not markedly influenced in the detection of early tumor stages (Tis-T2), low grade (G1-G2), lesser tumor size ≤2 cm, and negative lymph nodes status (AUC=0.79, 0.74, 0.74, and 0.85, respectively). Conclusions: Combined use of NMP-52, collagen III, and MMP-1 can serve as a potential biomarker for BrCa diagnosis. This combination is likely to improve the clinical early tumor diagnosis.
Keywords
Breast cancer; Collagen; Matrix metalloproteinase; Nuclear matrix protein; Score
Statistics
Article View: 142
PDF Download: 166